Network analysis of metabolite GWAS hits

Implication of CPS1 and the urea cycle in weight maintenance

Matone, Alice; Scott-Boyer, Marie-Pier; Carayol, Jerome; Fazelzadeh, Parastoo; Lefebvre, Gregory C.; Valsesia, Armand; Charon, Celine; Vervoort, Jacques; Astrup, Arne; Saris, Wim H M; Morine, Melissa; Hager, Jörg

Published in:
P L o S One

DOI:
10.1371/journal.pone.0150495

Publication date:
2016

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Matone, A., Scott-Boyer, M-P., Carayol, J., Fazelzadeh, P., Lefebvre, G. C., Valsesia, A., ... Hager, J. (2016). Network analysis of metabolite GWAS hits: Implication of CPS1 and the urea cycle in weight maintenance. P L o S One, 11(3), [e0150495]. https://doi.org/10.1371/journal.pone.0150495
Network Analysis of Metabolite GWAS Hits: Implication of CPS1 and the Urea Cycle in Weight Maintenance

Alice Matone1☯, Marie-Pier Scott-Boyer1☯, Jerome Carayol2, Parastoo Fazelzadeh3, Gregory Lefebvre2, Armand Valsesia2, Celine Charon4, Jacques Vervoort3, Arne Astrup5, Wim H. M. Saris6, Melissa Morine1*, Jörg Hager2*

1 The Microsoft Research—University of Trento Centre for Computational Systems Biology (COSBI), Rovereto, Italy, 2 Nestlé Institute of Health Sciences SA, Lausanne, Switzerland, 3 Nutrition, Metabolism & Genomics group, University of Wageningen, Wageningen, Netherlands, 4 CEA-Genomics Institute- National Genotyping Center, Evry, France, 5 Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark, 6 Dept of Human Biology Medical and Health Science Faculty, University of Maastricht, Maastricht, Netherlands

☯ These authors contributed equally to this work.
* Jorg.Hager@rd.nestle.com

Abstract

Background and Scope

Weight loss success is dependent on the ability to refrain from regaining the lost weight in time. This feature was shown to be largely variable among individuals, and these differences, with their underlying molecular processes, are diverse and not completely elucidated. Altered plasma metabolites concentration could partly explain weight loss maintenance mechanisms. In the present work, a systems biology approach has been applied to investigate the potential mechanisms involved in weight loss maintenance within the Diogenes weight-loss intervention study.

Methods and Results

A genome wide association study identified SNPs associated with plasma glycine levels within the CPS1 (Carbamoyl-Phosphate Synthase 1) gene (rs10206976, p-value = 4.709e-11 and rs12613336, p-value = 1.368e-08). Furthermore, gene expression in the adipose tissue showed that CPS1 expression levels were associated with successful weight maintenance and with several SNPs within CPS1 (cis-eQTL). In order to contextualize these results, a gene-metabolite interaction network of CPS1 and glycine has been built and analyzed, showing functional enrichment in genes involved in lipid metabolism and one carbon pool by folate pathways.

Conclusions

CPS1 is the rate-limiting enzyme for the urea cycle, catalyzing carbamoyl phosphate from ammonia and bicarbonate in the mitochondria. Glycine and CPS1 are connected through the one-carbon pool by the folate pathway and the urea cycle. Furthermore, glycine could...
be linked to metabolic health and insulin sensitivity through the betaine osmolyte. These considerations, and the results from the present study, highlight a possible role of \textit{CPS1} and related pathways in weight loss maintenance, suggesting that it might be partly genetically determined in humans.

\section*{Introduction}

Obesity is a major risk factor for cardiovascular diseases, hypertension, insulin resistance and type 2 diabetes as well as some cancers [1,2]. Multiple studies have shown that weight loss achieved through energy restricted dietary interventions improves the metabolic dysfunctions involved in metabolic syndrome [3–5], and prevents type 2 diabetes. However, the capacity to lose weight and, in particular, to avoid weight regain, shows inter-individual variability that hitherto cannot be explained only by differences in exogenous environmental exposures and lifestyle factors [6,7]. Several studies have shown that this heterogeneity is, at least in part, due to physiological/molecular metabolism differences [8,9]. For example, overfeeding studies have demonstrated a threefold difference in energy efficiency, in turning calories into body mass between individuals [10]. Still, the molecular mechanisms contributing to successful weight loss/maintenance remain poorly understood. Obesity and weight change are complex, and, in order to aid their comprehension, an integrated, multidisciplinary approach is necessary. Here, we show results from combining different types of “omics” data from a large dietary intervention study, with a network analysis approach, in order to elucidate the biological functions involved in the weight maintenance capacity in humans.

Molecular phenotypes can be used as an intermediate to help in identifying relationships between genetic variants and a more global phenotype, such as weight maintenance. For instance, blood metabolite profile can be used to differentiate between obese and lean individuals [11]. For example, plasma glycine levels were negatively correlated with BMI and associated with genetic variants within the carbamoyl-phosphate synthase 1 (\textit{CPS1}) gene, which encodes for a mitochondrial enzyme that catalyzes the synthesis of carbamoyl phosphate from ammonia and bicarbonate [12,13]. These observations raise the possibility that alterations in plasma metabolite concentrations could reflect changes of metabolic processes involved in weight maintenance [14].

The integration of experimental data with systems biology methods could point to possible not yet known pathways to explore [15,16]. With this aim, the utilization of metabolite-protein and protein-protein interaction networks, built from databases, is a powerful way to investigate metabolic pathways potentially correlated with the condition of interest [17]. Networks can allow the consideration of nodes and pathways that would not have been explored with other methodologies. For example, Emilsson et al. [18] constructed an extensive co-expression network on the basis of the human adipose tissue data, to investigate key functional modules associated with obesity, and found that many of the interconnected genes were also associated with the inflammatory response and pathways linked to macrophage activation. In the present work we built a metabolite/protein interaction network of \textit{CPS1} and glycine, in order to investigate whether there could be a link between the pathways in which these are involved, and the complex nature of weight loss and regain, in combination with genetic, metabolomic, transcriptomic and anthropometric data.

The presented results are based on data from one of the worldwide largest dietary intervention study, the Diet, Obesity, and Genes study (DioGenes) [19]. DioGenes is a multicenter, randomized controlled dietary intervention study, involving 8 European countries, which started
in 2005. 938 eligible adults underwent an 8-week weight-loss phase following a complete meal replacement low calorie diet (800–1000 kcal/day total energy intake). Subjects who achieved at least 8% weight loss (n = 773) were randomly assigned to one of five weight maintenance arms for 26-weeks. In this paper we will refer as baseline (BL), the initial state (before the study), post-weight loss (PWL) the time after the 8 weeks weight loss period and (PWM) the time point after the 6 months weight maintenance phase. The DioGenes study is unique in its availability of multiple “omics” data from the different time points, including metabolomics, proteomics, adipose tissue RNA expression and genotype data on all participants.

**Materials and Methods**

DioGenes was registered in ClinicalTrials.gov (NCT00 390637). Briefly, 932 overweight and obese adults in 8 European centers participated in a dietary program with an 8-week 800–1000 kcal/day whole meal replacement low-caloric diet (LCD; Modifast, Nutrition et Santé, France). Subjects achieving at least 8% of initial body weight loss were randomized to a 6-month ad libitum weight maintenance diet (WMD) consisting in one of four low-fat diets that differed in glycemic index and protein content, or a control diet as described in [20]. Abdominal subcutaneous fat biopsies from the DioGenes protocol were obtained by needle aspiration under local anesthesia after an overnight fast at baseline, at the end of LCD and at the end of WMD. All clinical investigations were performed according to standard operating procedures. Analysis of blood samples was performed at the Department of Clinical Biochemistry, Gentofte University Hospital, Denmark. The study was performed according to the latest version of the Declaration of Helsinki and the Current International Conference on Harmonization (ICH) guidelines. All subjects gave verbal and written informed consent. Ethical approval was obtained from all the regional Ethics Committees of the eight participating centers. The study protocol and informed consent document were approved by the Medical Ethical Committees of Maastricht University and the University of Copenhagen.

**Measurement of targeted blood metabolites**

After 12-hour overnight fast, venipuncture was performed in the morning. Fasting blood samples were obtained at each of the 3 CIDs for the analysis of blood metabolites, as also outlined in [20]. NMR measurements were performed by mixing serum samples (100 microliter) with 100 microliter buffer, transferring this to 3 mm NMR tubes and subsequent measurements on a Bruker Avance III NMR spectrometer with cryoprobe. The temperature for the measurements was 37°C and metabolites were determined from 1H J-RES data [21]. The spectra obtained were automatically aligned, phase corrected, base line corrected and integrated. Using the described approach, 36 metabolites could automatically be quantified from the NMR datasets. Eighteen of these metabolites (glucose, acetate, n-acetyl, acetoacetate, proline, glycine, alanine, leucine, isoleucine, valine, tyrosine, creatinine, creatine, lactate, 3-OH-butyrate, hydroxyisobutyrate, oxo-isovaleric acid, urea) passed QC and were included in the GWAS study.

**Genotype data**

Genomic DNA was extracted from the buffy coats with a salting out method. Genomic and amplified DNA samples were quality-checked, quantified and normalized to approximately 100 ng/ml and 2.0 mg before genotyping. High throughput SNP genotyping was carried out using the Illumina iScan Genotyping System (Illumina, San Diego, CA, USA). 748 individuals were genotyped using the Illumina 660W-Quad SNP chip. SNP genotyping was done in accordance with manufacturer’s protocols. The Integrated mapping information is based on NCBI’s
Pre-processing of the genotype data was performed with plink (v1.07), which is a free, open-source whole genome association analysis toolset, developed by Shaun Purcell at the Center for Human Genetic Research, Massachusetts General Hospital and Broad Institute of Harvard and MIT [22,23]. The parameters used were mind = 0.01 and geno = 0.01. Furthermore SNPs with MAF < 0.05 and SNPs not in hardy Weinberg equilibrium (p < 10^{-4}) were excluded leading to a set of 456,382 informative SNPs. Pair-wise linkage disequilibrium [24] was calculated with the LDlink web-based application using 1000 Genome phase 3 data (for the CEU population).

**Genome-wide Association Statistics**

For association analyses plink software was used. A principal component analysis was performed based on all SNPs after quality control. Principal components were used to control for genetic heterogeneity during association analyses. The number of subjects for which both genotype and metabolite data were available are 641. Linear regression was performed for each SNP for all of the 18 metabolites (NMR) that passed QC considering their level as quantitative traits with gender, age, center and ten first principal components form previous PCA as covariates. This model examines whether each additional allele could alter the trait by equal amounts across the three genotypes. The 5.0e-8 threshold was used to evaluate the significance of each association.

**Networks and gene enrichment**

Networks were built from the central nodes glycine and CPS1, respectively. Metabolite—gene interactions (glycine targets) were retrieved from Drug Bank 4.2 [25], while protein—protein interactions were retrieved from String 10 [26]. String interactions selection was restricted to the knowledge evidence type, which represents interactions gathered from curated databases. String interactions have a confidence score, which was restricted to above or equal to 0.7, as interactions above this threshold are considered to be in the high confidence range [27]. The networks were built up to 2 neighbors from the central nodes, in order to include a sufficient number of connections to investigate the possible biological pathways relevant to the process under investigation. Networks were built in R library igraph [28], while Cytoscape 3.0 was used for graphical representation. The David online tool [29,30] was used to perform gene pathway enrichment analysis (using KEGG pathways [31]). False discovery rate (FDR) adjusted p-value with a threshold of 0.05 was selected (this corresponded to a false discovery rate of 5%).

**Gene expression**

RNA extraction, storage and QC was performed as described in [32]. RNA-seq data from adipose tissues was generated using a pipeline for parallel job submission which consists of RNAS-tar, version 2.2.0.c [33], with standard parameters, for the alignment process, of samtools, version 0.1.18 [34], for sam/bam file manipulation, and bedtools multicov, version 2.16.2 [35], for computation of transcripts coverage. The genome reference used for mapping was NCBI build 37 (GRCh37).

**eQTL mapping**

eQTL analysis in adipose tissue was performed on a subset of 450 individuals from the Diogenes cohort where both the RNA-seq data at time BL and genotype data were available. Pre-processing of the genotype data was performed with plink [22,23] using the same parameters has for the GWAS, leading to a total of 482826 SNPs. The eQTL analysis was performed with the R
package MatrixEQTL [36] using a linear model with the following covariates: sex, age and sampling center and 10 first PCs of population stratification. A threshold of adjusted p-value (FDR) < 0.05 was set.

**Statistical methods**

The statistical software R 3.0.3 [37] was used for the statistical analysis. A p-value of 0.05 was defined as significance threshold except where otherwise mentioned. The function lm from the stats package in R was used for analyzing the relationship between BMI fold change (between post weight maintenance and post weight loss, computed as (BMI PWM-BMI PWL)/BMI PWL) and gene expression. The same functions were applied to investigate the difference in gene expression between weight maintainers (WMs), defined as subjects which BMI did not change more than 4% during the weight maintenance phase (n = 55) [38], and weight regainers (WRs), whose weight increased by more than 4% (n = 136). Outliers were removed according to the “outlier labeling rule” [39] (k = 1.5), using one iteration, when comparing gene expression in WM and WRs. The finally compared groups for CPS1 gene expression were of 132 and 53 for WM and WR, respectively. S2 Fig shows CPS1 gene expression box plots before and after outliers’ removal. Regressions were corrected for age and sex.

**Results**

**GWAS of glycine level**

Of the eighteen metabolites analyzed only two showed genome-wide significant associations with SNPs. We identified an association between rs2238732 in the PRODH gene and proline levels. The association of markers in the PRODH gene with proline levels has already been reported by Shin SY et al. [40]. However, neither proline levels nor any of the SNPs in PRODH associated with measure of weight loss/weight maintenance and were not pursued further. We also confirmed the genome-wide association between polymorphisms upstream of CPS1 gene and blood-derived glycine level in 641 European individuals from the population based DioGenes study [19].

These analyses have identified two loci at genome-wide significance (P < 5.0e-8) in CPS1: rs10206976 (chr 2:210749914 p-value = 4.709e-11, with allelic odds ratio (OR) = 1.23) and rs12613336 (chr 2:210704675 p-value = 1.368e-08, OR = 1.19) associated with the glycine level in the blood samples (Fig 1). The variant rs1047891 (chr2:210675783), causing the missense mutation Thr1412Asn, was identified as the most probable causal variant using a fine mapping approach [13]. This variant was not in the SNP array used in our study, but is in LD with the SNPs rs10206976 (r = 0.51 D-prime = 1) and rs12613336 (r = 0.5128, D-prime = 0.923).

**CPS1 eQTL analysis**

The gene expression profiling from RNA-seq in adipose tissues at baseline for 450 individuals in the DioGenes cohorts were used to find genetic associations with the CPS1 transcription levels. Genetic mapping of the expression of CPS1 revealed significant eQTLs (adjusted p-value (FDR) < 0.05). Among those, 17 SNPs were defined as cis-eQTLs since they were located within 100 kbp from the transcription start site of the gene that was measured. Fig 2 shows the association between CPS1 transcription level and the SNP rs3856348 showing the strongest association (p-value = 2.477e-24). Using the LDlink a web-based application [24], one of these SNPs was found to be in linkage disequilibrium (D-prime > 0.6, R-squared = 0.101) with the glycine associated GWAS SNP rs1047891 (see Table 1).
Glycine and \( \text{CPS1} \) networks

In order to explore the glycine and \( \text{CPS1} \) connected pathways and to better understand the link between \( \text{CPS1} \) and glycine at the molecular level, a database search was performed to identify protein–protein interactions for \( \text{CPS1} \), and protein–metabolite interactions for glycine. Findings from these searches were converted into networks, where nodes represent proteins (or glycine), and edges represent protein–protein (or glycine-protein) interactions. The glycine-centered network resulted in 383 nodes and the \( \text{CPS1} \)—centered network in 77 nodes. The merged glycine and \( \text{CPS1} \) network resulted in 427 nodes (33 shared nodes), shown in Fig 3.

Gene functional enrichment for the 426 genes in the \( \text{CPS1} \)—glycine network for KEGG pathways [31,41] showed enrichment for 22 terms (adjusted p-value (FDR) < 0.05), reported in S1 Fig. The top pathway for significance is the Neuroactive ligand-receptor interaction (adjusted

![Manhattan plot of Glycine](https://example.com/manhattan.png)
p-value (FDR) 3.48 e-36). Interestingly, the One carbon pool by folate pathway is represented at the seventh place, with a p-value of 1.45 e-10.

Weight maintenance and gene expression

In order to investigate whether there was a relation between weight maintenance and CPS1 gene expression, the latter was investigated in successful WMs and WRs individuals. WMs were defined as subjects whose BMI did not vary more than 4% during the weight maintenance phase, while WRs were defined as subjects whose weight increased by more than 4% [38].

CPS1 gene expression at the beginning of the weight maintenance phase was significantly different between the two groups (Fig 4, p-value = 0.04, correcting for age and sex).

The same analysis was performed for all the genes in the CPS1-Glycine network, and the expression value of 45 genes (adjusted p-value (FDR) < 0.1) at the beginning of the weight...
maintenance phase was significantly different between WMs and WRs. The significant genes and corresponding p-values are reported in Table 2.

Gene expression at the end of the weight maintenance phase of 426 genes within the CPS1-Glycine network was analyzed with respect to BMI variation between pre and post weight loss. In a multiple linear regression, the variation in expression of 10 genes was significantly (adjusted p-value (FDR) < 0.1) correlated with BMI variation during weight maintenance (Table 3).

Discussion

The results show that genetic variants in CPS1, the rate-limiting enzyme of the urea cycle, are strongly associated with plasma glycine levels, and that differences in the expression of CPS1 suggest a potential causative association with an individual’s capacity to maintain weight after weight loss. This shows the relevance of studying intermediate phenotypes, such as metabolites level, within GWAS results.

In order to insert the results into a broader biological context, building networks helped to identify pathways of interest that would not have been conventionally studied. Glycine is an important metabolite for some key pathways, like the urea cycle, the folate cycle and the one-carbon metabolism. Specifically, glycine provides a precursor pool for betaine, which is an important osmolyte and methyl donor. Betaine has been associated with metabolic, liver and heart health in humans [42]. A high betaine intake has been shown to correlate with higher insulin sensitivity and lower BMI in mice [42,43].

So how may genetic variants and the differences in CPS1 gene expression contribute to differences in the capacity to maintain weight? One possible model is that individuals who regain weight have a preference to use amino acids and proteins as energy source. They produce more NH4+, which induces CPS1 expression and leads to more urea. The individuals, who have less
amino acid and protein metabolism, use fat as energy source. They therefore produce less NH4+ and CPS1 is less induced. As a result of higher fat oxidation these individuals may be better at maintaining body weight. This is consistent with the observation that urea levels are higher in weight regainers. In general it has become clear that obese individuals are less flexible in the change from carbohydrate to fat oxidation leading to lower fat oxidation and insulin resistance [44]. The genetic variants influencing CPS1 gene expression would accentuate this effect and would also explain the observed association between the SNPs and glycine levels in the blood. Individuals with a genotype leading to higher CPS1 expression have less glycine (at the same input level of NH4+) and the individuals who express less CPS1 protein have more glycine in the blood. Glycine is a major biochemical mechanism to eliminate ammonia. Glycine conjugating with benzoic acid leads to hippuric acid, which is abundantly found in urine samples. Variations in CPS1 quantity and thus the glycine pool may also influence one-carbon metabolism and the bioavailability of betaine. It is noteworthy that the one-carbon metabolism, apart from providing one-carbon bodies for many building blocks in the cell, has been also shown to be linked more directly to mitochondrial function [45] and thus, to energy
Fig 4. CPS1 gene expression and weight maintenance. Box plots for CPS1 gene expression at PWL, for weight maintainers (WMs) and weight maintenance resistors (WRs), defined as ΔBMI < 4% and ΔBMI > 4% increase (p-value = 0.04, corrected for age and sex).

doi:10.1371/journal.pone.0150495.g004
| n | Gene symbol | p-value       | adjusted p-value (FDR) |
|---|-------------|---------------|-----------------------|
| 1 | POMC        | 7.66E-06      | 0.00121               |
| 2 | HRAS        | 8.87E-06      | 0.00121               |
| 3 | GPX1        | 7.14E-06      | 0.00121               |
| 4 | CREBBP      | 1.50E-05      | 0.00154               |
| 5 | TBL1X       | 3.05E-05      | 0.00209               |
| 6 | NCOA1       | 2.97E-05      | 0.00209               |
| 7 | GRIN3A      | 5.10E-05      | 0.003                 |
| 8 | RASGRF2     | 9.73E-05      | 0.005                 |
| 9 | TAF10       | 1.34E-04      | 0.00552               |
|10 | NCOA2       | 1.26E-04      | 0.00552               |
|11 | NF1         | 1.66E-04      | 0.00621               |
|12 | MTR         | 2.08E-04      | 0.00712               |
|13 | FYN         | 2.84E-04      | 0.00898               |
|14 | MED1        | 5.62E-04      | 0.0165                |
|15 | CNHI2       | 6.25E-04      | 0.0168                |
|16 | MDH2        | 6.97E-04      | 0.0168                |
|17 | SPTLC3      | 6.52E-04      | 0.0168                |
|18 | NCOA6       | 8.10E-04      | 0.0178                |
|19 | LPAR3       | 8.22E-04      | 0.0178                |
|20 | GSS         | 1.36E-03      | 0.028                 |
|21 | GPX4        | 1.52E-03      | 0.0297                |
|22 | GRHPR       | 1.79E-03      | 0.0335                |
|23 | MGST3       | 1.87E-03      | 0.0335                |
|24 | SPTLC2      | 3.35E-03      | 0.0453                |
|25 | ACY3        | 3.42E-03      | 0.0453                |
|26 | PPARA       | 3.39E-03      | 0.0453                |
|27 | ADCY9       | 3.46E-03      | 0.0453                |
|28 | SDSL        | 2.90E-03      | 0.0453                |
|29 | HCAR1       | 2.77E-03      | 0.0453                |
|30 | CCL28       | 3.30E-03      | 0.0453                |
|31 | ALDH7A1     | 3.53E-03      | 0.0453                |
|32 | CHD9        | 3.46E-03      | 0.0453                |
|33 | TAS2R41     | 3.78E-03      | 0.0471                |
|34 | GSTK1       | 4.04E-03      | 0.0489                |
|35 | GSTOP1      | 4.39E-03      | 0.0515                |
|36 | CHRM4       | 4.62E-03      | 0.0527                |
|37 | BAAT        | 5.40E-03      | 0.06                  |
|38 | GAL         | 6.65E-03      | 0.0643                |
|39 | PPP1CA      | 6.72E-03      | 0.0643                |
|40 | AKAP9       | 6.44E-03      | 0.0643                |
|41 | GSTO1       | 6.45E-03      | 0.0643                |
|42 | MTHFD2L     | 6.68E-03      | 0.0643                |
|43 | GFFT1       | 6.11E-03      | 0.0643                |
|44 | RUVBL2      | 7.46E-03      | 0.0697                |
|45 | GSTM3       | 1.07E-02      | 0.0973                |

Genes within the CPS1 glycine network for which expression levels at PWL is significantly different between WMs and WRs, after correction for age and sex (adjusted p-value < 0.1).

doi:10.1371/journal.pone.0150495.t002
homeostasis. It might therefore be that the difference in the expression of CPS1 protein, observed here ultimately impacts energy homeostasis, thereby contributing to the difference in energy efficiency and the capacity to maintain weight after weight loss. To our knowledge this is the first time that such a possible connection has been shown. Our results put a focus on further studies of the relationship between the urea cycle, folate cycle and one-carbon metabolism, on one hand, and energy metabolism on the other. It also provides further evidence that weight maintenance is partly genetically determined in humans [9,46].

The highlighted connections between CPS1, glycine and weight maintenance, are further supported by some of the genes in the CPS1—glycine network that are correlated with weight maintenance and BMI variation. It is worth of notice as, within the 45 genes which expression differed between weight maintainers and weight regainers (Table 2), some are involved in pathways that could be relevant to weight maintenance. For instance, several genes are involved in fatty acids and lipids metabolism (PPARA [47–49], ALDH7A1 [50,51], BAAT [52], PPP1CA [53] and SPTLC2 [54]). Two genes have a role within the one carbon pool by folate pathway, MTR [55] and MTHFD2L [56]. Furthermore, the following genes are involved in diabetes and insulin signaling: MDH2 [57], PPIA [58] and HRAS [59]. Also, within the 10 genes which expression significantly correlated with BMI fold change during the weight maintenance phase (Table 3), GNG2 [60] is involved in diabetes pathways, while ALAS1 has been shown to be induced in diabetes in mice [30,61].

One main limitation of the present study concerns the need for further experimental verification of the proposed biological meaning of the results. Although different analytical methods have been applied prior to draw the reported conclusions, deeper empirical investigation should be conducted, especially regarding the possible role of the highlighted genes, as well as the unresolved mechanistic links between SNPs and CPS1 expression and CPS1 expression and Glycine.

The use of biological networks from a priori knowledge, i.e. from databases, is useful for data integration and can help biological interpretation of the system by combining complementary viewpoints, each one addressing different aspects of the system. Also, merging a network analysis with independent experimental data can increase data confidence and help interpreting the link with the investigated phenotype, i.e. weight loss maintenance in this case. This is important especially when studying high-throughput data, which can be affected by noise and incompleteness [62].

### Table 3. Gene expression and BMI.

| n | Gene symbol | p-value | adjusted p-value (FDR) |
|---|-------------|---------|------------------------|
| 1 | ANXA1       | 0.0007  | 0.0595                 |
| 2 | APLN        | 0.0006  | 0.0595                 |
| 3 | GLUL        | 0.0004  | 0.0595                 |
| 4 | ALAS1       | 0.0003  | 0.0595                 |
| 5 | GNG2        | 0.0007  | 0.0595                 |
| 6 | GSR         | 0.0017  | 0.0902                 |
| 7 | C3AR1       | 0.0016  | 0.0902                 |
| 8 | CBS         | 0.0019  | 0.0902                 |
| 9 | GARS        | 0.0019  | 0.0902                 |
| 10| P2RY14      | 0.0022  | 0.0913                 |

Genes within the CPS1 glycine network which expression at PWM correlates with BMI fold change during the weight maintenance phase (adjusted p-value < 0.1, correcting for age and sex).

doi:10.1371/journal.pone.0150495.t003
Supporting Information

S1 Fig. CPS1 glycine network KEGG pathways gene enrichment. Gene enrichment performed with David for KEGG pathways. The dendrogram represents the distance within GO terms relatively to the number shared genes. The number of genes in each term is represented in the bar chart while the color of the bars represents the % of pathway coverage (i.e. the ratio of genes in the term in the network over the total number of genes in the term). The p-value for each term’s enrichment is reported in the plot (adjusted p-value (FDR) < 0.05).

(TIF)

S2 Fig. CPS1 gene expression and weight maintenance before (A) and after (B) outliers removal. Box plots for CPS1 gene expression at PWL, for weight maintainers (WMs) and weight maintenance resistors (WRs), defined as ΔBMI < 4% and ΔBMI > = 4% increase. A) WMs = 137, WRs = 55, p-value = 0.23. B) WMs = 132, WRs = 53, p-value = 0.04. Both regressions were corrected for age and sex.

(TIF)

Acknowledgments

The DIOGENES trial was funded by the European Commission, contract no. FP6-2005-513946. The funding source had no role in the study design, data collection, data analysis, data interpretation or writing of the report.

Author Contributions

Conceived and designed the experiments: JV AA WHMS JH. Performed the experiments: PF GL AV CC. Analyzed the data: AM MPSB PF MM JC. Wrote the paper: AM MPSB JH.

References

1. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol. 2010; 316: 104–8. doi: 10.1016/j.mce.2009.07.008 PMID: 19628019
2. Lean ME. Pathophysiology of obesity. Proc Nutr Soc. 2000; 59: 331–6. PMID: 10997648
3. Soare A, Weiss EP, Pozzilli P. Benefits of caloric restriction for cardiometabolic health, including type 2 diabetes mellitus risk. Diabetes Metab Res Rev. 2014; 30 Suppl 1: 41–7. doi: 10.1002/dmrr.2517 PMID: 24332291
4. Tumova E, Sun W, Jones PH, Vrablik M, Ballantyne CM, Hoogeveen RC. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013; 2013: 729515. doi: 10.1155/2013/729515 PMID: 24455214
5. Bales CW, Kraus WE. Caloric restriction: implications for human cardiometabolic health. J Cardiopulm Rehabil Prev. 33: 201–8. doi: 10.1097/HCR.0b013e318295019e PMID: 23748374
6. Frame B, Beal SL, Miller R, Barrett J, Burger P. Mixed effects modeling of weight change associated with placebo and pregabalin administration. J Pharmacokinet Pharmacodyn. 2007; 34: 753–70. doi: 10.1007/s10928-007-9067-z PMID: 17690866
7. Neilberg RH, Wing RR, Bray GA, Rebeussin DM, Rickman AD, Johnson KC, et al. Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study. Obesity (Silver Spring). 2012; 20: 704–8. doi: 10.1038/oby.2012.33
8. Dulloo AG. Suppressed thermogenesis as a cause for resistance to slimming and obesity rebound: adaptation or illusion? Int J Obes (Lond). Nature Publishing Group; 2007; 31: 201–3. doi: 10.1038/sj.ijo.0803537
9. Galgani J, Ravussin E. Energy metabolism, fuel selection and body weight regulation. Int J Obes (Lond). 2008; 32 Suppl 7: S109–19. doi: 10.1038/oby.2008.246
10. Bouchard C, Tremblay A, Després JP, Nadeau A, Lupien PJ, Thériault G, et al. The response to long-term overfeeding in identical twins. N Engl J Med. 1990; 322: 1477–82. doi: 10.1056/NEJM1990052432222101 PMID: 2336074
11. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009; 9: 251–61. doi: 10.1016/j.cmet.2009.04.004 PMID: 19438052

12. Xie W, Wood AR, Lyssenko V, Weedon MN, Knowles JW, Alkayyali S, et al. Genetic variants associated with glycine metabolism and their role in insulin sensitivity and type 2 diabetes. Diabetes. 2013; 62: 2141–50. doi: 10.2337/db12-0876 PMID: 23378610

13. Demirkan A, Henneman P, Verhoeven A, Dharuri H, Amin N, van Klinken JB, et al. Insight in Genome-Wide Association of Metabolite Quantitative Traits by Exome Sequence Analyses. PLoS Genet. 2015; 11: e1004385. doi:10.1371/journal.pgen.1004385 PMID: 25569235

14. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2011; 17: 53–6. doi:10.1038/nm.2307 PMID: 21432183

15. Ng A, Burststein B, Gao Q, Mollison E, Zvelebil M. Resources for integrative systems biology: from data through databases to networks and dynamic system models. Brief Bioinform. 2006; 7: 318–30. doi: 10.1093/bib/bbl036 PMID: 17040977

16. Faro A, Giordano D, Spampinato C. Combining literature text mining with microarray data: advances for system biology modeling. Brief Bioinform. 2012; 13: 61–82. doi: 10.1093/bib/bbr018 PMID: 21677032

17. Barabási A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2011; 12: 66–8. doi:10.1038/nrg2918 PMID: 21164525

18. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, et al. Genetics of gene expression and its effect on disease. Nature. 2008; 452: 423–8. doi: 10.1038/nature06758 PMID: 18344981

19. Saris WHM. DiOGenes: an integrated multidisciplinary approach to the obesity problem in Europe. Nutr Bull. 2005; 30: 188–193. doi: 10.1111/j.1467-3010.2005.00496.x

20. Larsen TM, Dalskov S-M, van Baak M, Jebb SA, Papadaki A, Pfeiffer AFH, et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med. 2010; 363: 2102–13. doi: 10.1056/NEJMoa1007137 PMID: 21105792

21. Fonville JM, Maher AD, Coen M, Holmes E, Lindon JC, Nicholson JK. Evaluation of full-resolution J-resolved 1H NMR projections of biofluids for metabonomics information retrieval and biomarker identification. Anal Chem. 2010; 82: 1811–21. doi: 10.1021/ac902443k PMID: 20131799

22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81: 559–75. doi: 10.1086/519795 PMID: 1701901

23. Purcell S. PLINK: Whole genome data analysis toolset (v 1.07) [Internet]. Accessed: 7 January 2015. Available: http://pngu.mgh.harvard.edu/~purcell/plink/

24. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015; 31: 3555–7. doi:10.1093/bib/bvz267 PMID: 26139635

25. Knox C, Law V, Jewison T, Liu P, Ly S, Frolikis A, et al. DrugBank 3.0: a comprehensive resource for drugs. Nucleic Acids Res. 2011; 39: D1035–41. doi: 10.1093/nar/gkq1126 PMID: 21059682

26. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015; 43: D447–52. doi: 10.1093/nar/gku1003 PMID: 25352553

27. von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005; 33: D433–7. doi: 10.1093/nar/gki005 PMID: 15608232

28. Csardi G, Nepusz T. The igraph software package for complex network research. Fundam Inform. 2006; 74(1–2): 97–109. doi: 10.1007/s10799-006-9106-z

29. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37: 1–13. doi: 10.1093/nar/gkn923 PMID: 19333633

30. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44–57. doi: 10.1038/nprot.2008.211 PMID: 19131956

31. Kanehisa M, Goto S, Yamanishi Y, Nishimura K, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014; 42: D199–205. doi: 10.1093/nar/gkt1076 PMID: 24214961
32. Viguerie N, Montastier E, Maoret J-J, Roussel B, Combes M, Valle C, et al. Determinants of human adipose tissue gene expression: impact of diet, sex, metabolic status, and cis genetic regulation. Gibson G, editor. PLoS Genet. Public Library of Science; 2012; 8: e1002959. doi: 10.1371/journal.pgen.1002959 PMID: 23028366

33. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29: 15–21. doi: 10.1093/bioinformatics/bts635 PMID: 23104886

34. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25: 2078–9. doi: 10.1093/bioinformatics/btp352 PMID: 19505943

35. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26: 841–2. doi: 10.1093/bioinformatics/btp352 PMID: 20110278

36. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics. 2012; 28: 1353–8. doi: 10.1093/bioinformatics/bts163 PMID: 22492648

37. R Development Core Team. R: A language and environment for statistical computing. In: R Foundation for Statistical Computing, Vienna, Austria [Internet]. 2008 Accessed: 7 January 2015. ISBN 3-900051-07-0

38. Abildso CG, Schmid O, Byrd M, Zizzi S, Quartiroli A, Fitzpatrick SJ. Predictors of weight loss maintenance following an insurance-sponsored weight management program. J Obes. 2014; 2014: 736080. doi:10.1155/2014/736080 PMID: 24738027

39. Hoaglin DC, Iglewicz B, Tukey JW. Performance of Some Resistant Rules for Outlier Labeling. Taylor & Francis Group; 1986;

40. Shin S, Fauman EB, Petersen A, Krumsiek J, Santos R, Huang J, et al. An atlas of genetic influences on human blood metabolites. 2014; 46: 543–550. doi:10.1038/ng.2982

41. Kanehsa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28: 27–30. PMID: 10592173

42. Craig SA. Betaine in human nutrition. Am J Clin Nutr. 2004; 80: 539–549. PMID: 15321791

43. Zeisel SH. Metabolic crosstalk between choline/1-carbon metabolism and energy homeostasis. Clin Chem Lab Med. 2013; 51: 467–75. doi: 10.1515/ccim-2012-0518 PMID: 23072856

44. Kroetz DL, Yook P, Costet P, Bianchi P, Pineau T. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem. 1998; 273: 31581–9. PMID: 9813074

45. Issemann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol. 1993; 11: 37–47. doi: 10.1677/jme.0.0110037 PMID: 8240670

46. Yoon M, Lee H, Jeong S, Kim J-J, Nicol CJ, Nam KW, et al. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem. 1998; 273: 31561–9. PMID: 9813074

47. Guanje C, Yuanxiu C, Jie Z, Ayo D, Hanxia H, Herrie L, et al. A Common Variant in the ALDH7A1 Gene is Significantly Associated with Obesity in West Africans. 68th scientific sessions of American Diabetes Association. 2008.

48. Zhou J-B, Yang J-K, Zhao L, Xin Z. Variants in KCNQ1, AP3S1, MAN2A1, and ALDH7A1 and the risk of type 2 diabetes in the Chinese Northern Han population: a case-control study and meta-analysis. Med Sci Monit. International Scientific Information, Inc.; 2010; 16: BR179–83. PMID: 20512086

49. Hunt MC, Siponen MI, Alexson SEH. The emerging role of acyl-CoA thioesterases and acyltransferases in regulating peroxisomal lipid metabolism. Biochim Biophys Acta. 2012; 1822: 1397–410. doi: 10.1016/j.bbadis.2012.03.009 PMID: 22465940

50. Qiu J, Ni Y, Gong H, Fei L, Pan X, Guo M, et al. Identification of differentially expressed genes in omental adipose tissues of obese patients by suppression subtractive hybridization. Biochem Biophys Res Commun. 2007; 352: 469–78. doi: 10.1016/j.bbrc.2006.11.049 PMID: 17129576
54. Merrill JA, Sandhoff K. Sphingolipids: Metabolism and cell signaling. Biochemistry of Lipids, Lipoproteins, and Membranes. Elsevier; 2002. pp. 373–407.

55. Fredriksen Å, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolite phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat. 2007; 28: 856–865. doi: 10.1002/humu.20522 PMID: 17436311

56. Bolusani S, Young BA, Cole NA, Tibbetts AS, Momb J, Bryant JD, et al. Mammalian MTHFD2L Encodes a Mitochondrial Methylenetetrahydrofolate Dehydrogenase Isozyme Expressed in Adult Tissues. J Biol Chem. 2011; 286: 5166–5174. doi: 10.1074/jbc.M110.196840 PMID: 21163947

57. Hussey SE, Sharoff CG, Garnham A, Yi Z, Bowen BP, Mandarino LJ, et al. Effect of Exercise on the Skeletal Muscle Proteome in Patients with Type 2 Diabetes. Med Sci Sport Exerc. 2013; 45: 1069–1076. doi: 10.1249/MSS.0b013e3182814917

58. Liolitsa D. Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2002; 73: 261–266. doi: 10.1136/jnnp.73.3.261 PMID: 12185156

59. Khan AA, Ahmad J. Identification of crosstalk in Insulin pathway using Pathway Logic. 2013 IEEE 9th International Conference on Emerging Technologies (ICET). IEEE; 2013. pp. 1–6. 10.1109/ICET.2013.6743529

60. Torkamani A, Topol EJ, Schork NJ. Pathway analysis of seven common diseases assessed by genome-wide association. Genomics. 2008; 92: 265–72. doi: 10.1016/j.ygeno.2008.07.011 PMID: 18722519

61. Olivier LM, Davio C, Batlle AM del C, Gerez EN. ALAS1 gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice. Biochem J. 2012; 442: 303–10. doi: 10.1042/BJ20111005 PMID: 22070747

62. Merico D, Gfeller D, Bader GD. How to visually interpret biological data using networks. Nat Biotechnol. Nature Publishing Group; 2009; 27: 921–4. doi: 10.1038/nbt.1567 PMID: 19816451